Investigating genetic factors in a common type of childhood leukemia
Official title: Repeat enhancers as drivers of ETV6-RUNX1+ and ETV6-RUNX1-like B-lymphoblastic leukemia
Funded at University of Michigan at Ann Arbor · NIH-11130145 · Data updated 2026-11-12
This study is looking at how certain genetic changes in children with B-cell acute lymphoblastic leukemia (B-ALL) can affect their cancer, especially focusing on the ETV6 gene, to help find better treatments for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $500,719 |
| NIH project number | 1R01CA289045-01A1 |
| Project ID | NIH-11130145 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 11 years old who have been diagnosed with B-cell acute lymphoblastic leukemia, particularly those with ETV6 gene alterations.
✕Less likely to help
Patients with other types of leukemia or those over the age of 11 may not benefit from this research.
What this research studies
This research focuses on understanding the genetic mechanisms behind B-cell acute lymphoblastic leukemia (B-ALL) in children, particularly those with ETV6 gene alterations. The team will explore how specific genetic changes affect the behavior of leukemia cells, using human cell lines and samples to uncover the role of certain DNA sequences known as GGAA repeats. By studying these mechanisms, the research aims to provide insights that could lead to better treatments for affected children.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies and outcomes for children diagnosed with B-ALL.
How similar studies have gone: Previous research has shown promise in understanding genetic factors in leukemia, but this specific approach focusing on GGAA repeat enhancers is relatively novel.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Ryan, Russell James Hubbard — University of Michigan at Ann Arbor
- Study coordinator: Ryan, Russell James Hubbard
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.